Metal complexes in cancer chemotherapy

Metal complexes in cancer chemotherapy - general remarks, B.K. Keppler platinum an dnon-platinum complexes in clinical trials, M.E. Hein provisions for international approval of metal complexes in anti-cancer therapy, F.-Th. Saur mechanism of action of tumour inhibiting metal complexes, E. Holler platinum complexes with specific activity against hormone-dependent tumours, E. von Angerer platinum phosphonato complexes with particular activity against bone malignancies - an evaluation of an experimental model highly predictive for the clinical situation, Th. Kelenner et al ruthenium complexes - potential poles in anti-cancer pharmaceuticals, M.J. Clarke the development of tumour-inhibiting ruthenium dimethylsulfoxide complexes, G. Mestroni et al new tumour-inhibiting ruthenium complexes, B.K. Keppler et al gold complexes in cancer chemotherapy, O.M. Ni Dhubhghaill and P.J. Sadler clinical experience with tumour-inhibiting gallium complexes, Ph. Collery and C. Pechery antitumour bis(cyclopentadienyl)metal complexes, P. Koepf-Maier budotitane, a new tumou-inhibiting titanium compound - preclinical and clinical development, B.K. Kepper et al metal complexes with specific activity against colorectal tumours - evaluation of a tumour model close to the clinical situation, M.R. Berger et al diorganotin derivatives of dipeptides and mercaptoamino acids - antitumour agent candidates?, F. Huber and R. Barbieri tin analogues of cisplatin, A.J. Crowe in vitro antitumour activity of organotin(IV derivatives of salicylic acid and related compounds, M. Gielen et al interactions of antitumour metal complexes with serum proteins - perspectives for anticancer drug development, F. Kratz.